Severe Neurotoxicity Associated with supra-therapeutic Efavirenz concentrations: a retrospective cohort study

phenotype

[1]  G. Montepiedra,et al.  Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping , 2020, Clinical pharmacology and therapeutics.

[2]  M. Dheda.  Efavirenz and neuropsychiatric effects , 2017, Southern African journal of HIV medicine.

[3]  M. Setshedi,et al.  Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa , 2016, AIDS.

[4]  J. Farrar,et al.  Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis , 2016, Antimicrobial Agents and Chemotherapy.

[5]  F. Vaida,et al.  Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients , 2016, Journal of NeuroVirology.

[6]  D. Podzamczer,et al.  Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial , 2015, Journal of acquired immune deficiency syndromes.

[7]  J. Esplugues,et al.  Efavirenz and the CNS: what we already know and questions that need to be answered. , 2015, The Journal of antimicrobial chemotherapy.

[8]  D. Moore,et al.  Efavirenz as a cause of ataxia in children. , 2015, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[9]  V. Víctor,et al.  Mitochondrial (dys)function – a factor underlying the variability of efavirenz‐induced hepatotoxicity? , 2015, British journal of pharmacology.

[10]  C. Masimirembwa,et al.  CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe , 2015, BMC Pharmacology and Toxicology.

[11]  K. Dooley,et al.  Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. , 2015, The Journal of infectious diseases.

[12]  Ying Yang,et al.  Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  G. Maartens,et al.  Neuronal toxicity of efavirenz: a systematic review , 2013, Expert opinion on drug safety.

[14]  C. Kenyon,et al.  Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia. , 2012, British journal of clinical pharmacology.

[15]  K. Ruxrungtham,et al.  Body Weight Cutoff for Daily Dosage of Efavirenz and 60-Week Efficacy of Efavirenz-Based Regimen in Human Immunodeficiency Virus and Tuberculosis Coinfected Patients Receiving Rifampin , 2009, Antimicrobial Agents and Chemotherapy.

[16]  A. Mangili,et al.  Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Gelman,et al.  Use of CD45 gating in three and four-color flow cytometric immunophenotyping: guideline from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 2002, Cytometry.

[18]  Louw Jh.  Groote Schuur Hospital. , 1978, SA nursing journal. SA verplegingstydskrif.

[19]  M. Glick,et al.  HIV-Infected Patients , 2001 .